Literature DB >> 15811255

The PEACE study: limiting the role of angiotensin-converting enzyme inhibitors in stable coronary artery disease.

Richard T Lee.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15811255     DOI: 10.1007/s11883-005-0008-2

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  7 in total

1.  The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis.

Authors:  Georg Nickenig; David G Harrison
Journal:  Circulation       Date:  2002-01-22       Impact factor: 29.690

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  ACE inhibitors for patients with vascular disease without left ventricular dysfunction--may they rest in PEACE?

Authors:  Bertram Pitt
Journal:  N Engl J Med       Date:  2004-11-07       Impact factor: 91.245

Review 4.  The clinical use of angiotensin-converting enzyme inhibitors.

Authors:  Joseph Wong; Rajiv A Patel; Peter R Kowey
Journal:  Prog Cardiovasc Dis       Date:  2004 Sep-Oct       Impact factor: 8.194

5.  Angiotensin-converting-enzyme inhibition in stable coronary artery disease.

Authors:  Eugene Braunwald; Michael J Domanski; Sarah E Fowler; Nancy L Geller; Bernard J Gersh; Judith Hsia; Marc A Pfeffer; Madeline M Rice; Yves D Rosenberg; Jean L Rouleau
Journal:  N Engl J Med       Date:  2004-11-07       Impact factor: 91.245

6.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

Authors:  K M Fox
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

Review 7.  Angiotensin II-mediated development of vascular diseases.

Authors:  Alan Daugherty; Lisa Cassis
Journal:  Trends Cardiovasc Med       Date:  2004-04       Impact factor: 6.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.